In vitro evolution of allergy vaccine candidates, with maintained structure, but reduced B cell and T cell activation capacity

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Nilsson, Ola B ^a   Adedoyin, Justus ^a   Rhyner, Claudio ^b   Neimert Andersson, Theresa ^a   Grundström, Jeanette ^a   Berndt, Kurt D ^a   Crameri, Reto ^b   Grönlund, Hans ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALLERGY VACCINE; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G ANTIBODY; UNCLASSIFIED DRUG; VACCINE;

ALLERGY; ANAPHYLAXIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASTHMA; B LYMPHOCYTE; BASOPHIL DEGRANULATION; CAT ALLERGY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PROTEIN BINDING; PROTEIN EXPRESSION; T LYMPHOCYTE; AMINO ACID SEQUENCE; ANIMAL; BAGG ALBINO MOUSE; BASOPHIL; CAT; CHEMISTRY; DESENSITIZATION; ESCHERICHIA COLI; FEMALE; GENE LIBRARY; HYPERSENSITIVITY; IMMUNOLOGY; METABOLISM; METHODOLOGY; MOLECULAR GENETICS; MUTATION; PEPTIDE LIBRARY; SEQUENCE HOMOLOGY;

FELIS CATUS;

AMINO ACID SEQUENCE; ANIMALS; B-LYMPHOCYTES; BASOPHILS; CATS; DESENSITIZATION, IMMUNOLOGIC; ESCHERICHIA COLI; FEMALE; GENE LIBRARY; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; MOLECULAR SEQUENCE DATA; MUTATION; PEPTIDE LIBRARY; SEQUENCE HOMOLOGY, AMINO ACID; T-LYMPHOCYTES;

EID: 80052768250     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024558     Document Type: Article

References (42)

1. Plaschke P, Janson C, Norrman E, Bjornsson E, Lundback B, et al. (1996) Skin prick tests and specific IgE in adults from three different areas of Sweden. Allergy 51: 461-472.
2. Plaschke P, Janson C, Norrman E, Bjornsson E, Ellbjar S, et al. (1999) Association between atopic sensitization and asthma and bronchial hyperresponsiveness in swedish adults: pets, and not mites, are the most important allergens. J Allergy Clin Immunol 104: 58-65.
3. van Ree R, van Leeuwen WA, Bulder I, Bond J, Aalberse RC, (1999) Purified natural and recombinant Fel d 1 and cat albumin in in vitro diagnostics for cat allergy. J Allergy Clin Immunol 104: 1223-1230.
4. Partti-Pellinen K, Marttila O, Makinen-Kiljunen S, Haahtela T, (2000) Occurrence of dog, cat, and mite allergens in public transport vehicles. Allergy 55: 65-68.
5. Lau S, Illi S, Platts-Mills TA, Riposo D, Nickel R, et al. (2005) Longitudinal study on the relationship between cat allergen and endotoxin exposure, sensitization, cat-specific IgG and development of asthma in childhood-report of the German Multicentre Allergy Study (MAS 90). Allergy 60: 766-773.
6. Kaiser L, Gronlund H, Sandalova T, Ljunggren HG, van Hage-Hamsten M, et al. (2003) The crystal structure of the major cat allergen Fel d 1, a member of the secretoglobin family. J Biol Chem 278: 37730-37735.
7. Gronlund H, Bergman T, Sandstrom K, Alvelius G, Reininger R, et al. (2003) Formation of disulfide bonds and homodimers of the major cat allergen Fel d 1 equivalent to the natural allergen by expression in Escherichia coli. J Biol Chem 278: 40144-40151.
8. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, et al. (2005) A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 11: 446-449.
9. Schmitz N, Dietmeier K, Bauer M, Maudrich M, Utzinger S, et al. (2009) Displaying Fel d1 on virus-like particles prevents reactogenicity despite greatly enhanced immunogenicity: a novel therapy for cat allergy. J Exp Med 206: 1941-1955.
10. Williams GS, Oxenius A, Hengartner H, Benoist C, Mathis D, (1998) CD4+ T cell responses in mice lacking MHC class II molecules specifically on B cells. Eur J Immunol 28: 3763-3772.
11. Jardetzky TS, Brown JH, Gorga JC, Stern LJ, Urban RG, et al. (1996) Crystallographic analysis of endogenous peptides associated with HLA-DR1 suggests a common, polyproline II-like conformation for bound peptides. Proc Natl Acad Sci U S A 93: 734-738.
12. Infuhr D, Crameri R, Lamers R, Achatz G, (2005) Molecular and cellular targets of anti-IgE antibodies. Allergy 60: 977-985.
13. Ali FR, Kay AB, Larche M, (2007) Airway hyperresponsiveness and bronchial mucosal inflammation in T cell peptide-induced asthmatic reactions in atopic subjects. Thorax 62: 750-757.
14. Morgan WJ, Crain EF, Gruchalla RS, O'Connor GT, Kattan M, et al. (2004) Results of a home-based environmental intervention among urban children with asthma. N Engl J Med 351: 1068-1080.
15. Kattan M, Stearns SC, Crain EF, Stout JW, Gergen PJ, et al. (2005) Cost-effectiveness of a home-based environmental intervention for inner-city children with asthma. J Allergy Clin Immunol 116: 1058-1063.
16. Crameri R, (2007) Allergy vaccines: dreams and reality. Expert Rev Vaccines 6: 991-999.
17. Larche M, Akdis CA, Valenta R, (2006) Immunological mechanisms of allergen-specific immunotherapy. Nat Rev Immunol 6: 761-771.
18. Gehlhar K, Schlaak M, Becker WM, Bufe A, (1999) Monitoring allergen immunotherapy of pollen-allergic patients: the ratio of allergen-specific IgG4 to IgG1 correlates with clinical outcome. Clin Exp Allergy 29: 497-506.
19. Ball T, Fuchs T, Sperr WR, Valent P, Vangelista L, et al. (1999) B cell epitopes of the major timothy grass pollen allergen, phl p 1, revealed by gene fragmentation as candidates for immunotherapy. FASEB J 13: 1277-1290.
20. van Neerven RJ, Wikborg T, Lund G, Jacobsen B, Brinch-Nielsen A, et al. (1999) Blocking antibodies induced by specific allergy vaccination prevent the activation of CD4+ T cells by inhibiting serum-IgE-facilitated allergen presentation. J Immunol 163: 2944-2952.
21. Strait RT, Morris SC, Finkelman FD, (2006) IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and Fc gamma RIIb cross-linking. J Clin Invest 116: 833-841.
22. Bousquet J, Lockey R, Malling HJ, (1998) Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J Allergy Clin Immunol 102: 558-562.
23. Werfel T, Breuer K, Rueff F, Przybilla B, Worm M, et al. (2006) Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 61: 202-205.
24. Mellerup MT, Hahn GW, Poulsen LK, Malling H, (2000) Safety of allergen-specific immunotherapy. Relation between dosage regimen, allergen extract, disease and systemic side-effects during induction treatment. Clin Exp Allergy 30: 1423-1429.
25. Valenta R, Niederberger V, (2007) Recombinant allergens for immunotherapy. J Allergy Clin Immunol 119: 826-830.
26. Larche M, (2007) Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 119: 906-909.
27. Purohit A, Niederberger V, Kronqvist M, Horak F, Gronneberg R, et al. (2008) Clinical effects of immunotherapy with genetically modified recombinant birch pollen Bet v 1 derivatives. Clin Exp Allergy 38: 1514-1525.
28. Haselden BM, Kay AB, Larché M, (1999) Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 189: 1885-1894.
29. Counsell CM, Bond JF, Ohman JL Jr, Greenstein JL, Garman RD, (1996) Definition of the human T-cell epitopes of Fel d 1, the major allergen of the domestic cat. J Allergy Clin Immunol 98: 884-894.
30. Oldfield WL, Larché M, Kay AB, (2002) Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 360: 47-53.
31. Campbell JD, Buckland KF, McMillan SJ, Kearley J, Oldfield WL, et al. (2009) Peptide immunotherapy in allergic asthma generates IL-10-dependent immunological tolerance associated with linked epitope suppression. J Exp Med 206: 1535-1547.
32. Niederberger V, Horak F, Vrtala S, Spitzauer S, Krauth MT, et al. (2004) Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci U S A 101 (Suppl 2): 14677-14682.
33. Engel E, Richter K, Obermeyer G, Briza P, Kungl AJ, et al. (1997) Immunological and biological properties of Bet v 4, a novel birch pollen allergen with two EF-hand calcium-binding domains. J Biol Chem 272: 28630-28637.
34. Niemi M, Jylha S, Laukkanen ML, Soderlund H, Makinen-Kiljunen S, et al. (2007) Molecular interactions between a recombinant IgE antibody and the beta-lactoglobulin allergen. Structure 15: 1413-1421.
35. Laver WG, Air GM, Webster RG, Smith-Gill SJ, (1990) Epitopes on protein antigens: misconceptions and realities. Cell 61: 553-556.
36. Neimert-Andersson T, Thunberg S, Swedin L, Wiedermann U, Jacobsson-Ekman G, et al. (2008) Carbohydrate-based particles reduce allergic inflammation in a mouse model for cat allergy. Allergy 63: 518-526.
37. Frew AJ, (1993) Allergen immunotherapy. J Allergy Clin Immunol 125: S306-313.
38. Gafvelin G, Thunberg S, Kronqvist M, Gronlund H, Gronneberg R, et al. (2005) Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol 138: 59-66.
39. Madhurantakam C, Nilsson OB, Uchtenhagen H, Konradsen J, Saarne T, et al. (2001) Crystal Structure of the Dog Lipocalin Allergen Can f 2: Implications for Cross-reactivity to the Cat Allergen Fel d 4. J Mol Biol.
40. Saarne T, Grönlund H, Kull I, Almqvist C, Wickman M, et al. (2009) Cat sensitization identified by recombinant Fel d 1 several years before symptoms- results from the BAMSE cohort. Pediatr Allergy Immunol.
41. Crameri R, Hemmann S, Blaser K, (1996) PJuFo: a phagemid for display of cDNA libraries on phage surface suitable for selective isolation of clones expressing allergens. Adv Exp Med Biol 409: 103-110.
42. Saarne T, Kaiser L, Rasool O, Huecas S, van Hage-Hamsten M, et al. (2003) Cloning and characterisation of two IgE-binding proteins, homologous to tropomyosin and alpha-tubulin, from the mite Lepidoglyphus destructor. Int Arch Allergy Immunol 130: 258-265.